FAQ

somatostatin analogue therapy

Known as: Somatostatin Analog Therapy, therapy, somatostatin analogue 
Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1987-2018
024619872018

Related topics

Related topics

1 relation
Hormone Therapy

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
somatostatin analogue therapy
Hormone Therapy

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue.
BACKGROUND Spontaneous hyperinsulinaemic hypoglycaemia following gastric bypass surgery (GBS) is increasingly recognised. However… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2009
2009
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
OBJECTIVE In acromegaly, 25-50% of patients respond inadequately to conventional long-acting somatostatin analogue (SSA) therapy… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.
BACKGROUND The prevalence of gallstones (GS) is increased in acromegaly and further increased by somatostatin analogue (SA… (More)
Is this relevant?
2006
2006
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly.
In many centres, a test dose (TD) of octreotide is administered before commencing somatostatin analogue therapy (SAT), although… (More)
Is this relevant?
2005
2005
The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
OBJECTIVE In the treatment of acromegaly, a 'test dose' of octreotide is recommended prior to the use of depot somatostatin… (More)
Is this relevant?
2001
2001
Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
INTRODUCTION Neuroendocrine tumors often metastasize to the liver and present with disabling hormonal symptoms. Hepatic artery… (More)
Is this relevant?
2000
2000
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
BACKGROUND The recent introduction of the depot somatostatin analogues octreotide LAR and lanreotide represent major advances in… (More)
Is this relevant?
1994
1994
Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies.
BACKGROUND/AIMS Previous studies have shown that secretory losses in patients with end jejunostomy syndrome (EJS) on home… (More)
Is this relevant?
1991
1991
Somatostatin analogue treatment inhibits post-resectional adaptation of the small bowel in rats.
Post-resectional hyperplasia is the phenomenon in which residual small bowel increases in size and absorptive capacity after… (More)
Is this relevant?